Compositions and methods for the treatment of overactive bladder

Abstract

Disclosed herein are pharmaceutical compositions comprising oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising a therapeutically effective amount of oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, and. 
     
     
         2 . The pharmaceutical composition of  claim 1 , further comprising a pharmaceutically acceptable carrier, diluent, or excipient. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 1 mg to 30 mg. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg or in a dose of 10 mg. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 1 mg to 30 mg. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 1 mg or in a dose of 2 mg. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 1 mg to 30 mg. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg or in a dose of 10 mg. 
     
     
         11 . The pharmaceutical composition of  claim 2 , wherein the excipient is selected from the group consisting of lactose, sucrose, mannitol, sorbitol, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, sodium alginate, propylene glycol, and talc. 
     
     
         12 . A method of treating overactive bladder in a patient comprising
 administering to a patient in need thereof a therapeutically effective amount of oxybutynin or tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof   whereby a symptom of overactive bladder is alleviated or ameliorated.   
     
     
         13 . The method of  claim 12 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 1 mg to 30 mg. 
     
     
         14 . The method of  claim 12 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg. 
     
     
         15 . The method of  claim 12 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 1 mg to 30 mg. 
     
     
         16 . The method of  claim 12 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg or in a dose of 10 mg. 
     
     
         17 . The method of  claim 12 , wherein the tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 1 mg or in a dose of 2 mg. 
     
     
         18 . The method of  claim 12 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg or in a dose of 10 mg.